Brief: Basilea Pharmaceutica FY Operating Loss Down 52% To CHF 8.2 Million

Basilea Pharmaceutica AG, Allschwil

16/02/2021 06:18

Feb 16 (Reuters) - Basilea Pharmaceutica AG  BSLN.S :
    * FY OPERATING LOSS FELL 52 PERCENT TO -8.2 MILLION CHF
    * FY REVENUE 127.6 MILLION CHF VERSUS 134.4 MILLION CHF YEAR
AGO
    * FY NET LOSS -14.7 MILLION CHF VERSUS -22.4 MILLION CHF
LOSS YEAR
AGO
    * FY DILUTED LOSS PER SHARE 1.43 CHF VERSUS 2.08 CHF LOSS
YEAR AGO
    * BASILEA REPORTS STRONG 2020 FINANCIAL RESULTS AND
SIGNIFICANT
PROGRESS IN THE CLINICAL PIPELINE OF ITS ONCOLOGY ASSETS
    * FY OPERATING LOSS REDUCED BY OVER 50% TO CHF 8.2 MILLION
    * 2021 GUIDANCE: EXPECTING 38% - 51% GROWTH IN CRESEMBA AND
ZEVTERA NON-DEFERRED REVENUE CONTRIBUTIONS, STABLE EXPENSES AND
2021 YEAR-END CASH POSITION OF CHF 110 - 120 MILLION
    * TOTAL REVENUE IN 2020 DECREASED TO CHF 127.6 MILLION
(2019: CHF
134.4 MILLION)
    * FY NET LOSS WAS ALSO REDUCED SIGNIFICANTLY TO CHF 14.7
MILLION
(2019: CHF 22.4 MILLION),
    * 2021 ANTICIPATED OPERATING LOSS AMOUNTS TO CHF 13 - 23
MILLION,
WHICH IS BELOW OPERATING LOSS REPORTED FOR 2020
    * CASH AND INVESTMENTS ARE EXPECTED TO BE APPROXIMATELY CHF
110 -
120 MILLION AT YEAR-END 2021, EXCLUDING ANY POTENTIAL IMPACT
FROM A REDUCTION OF OUTSTANDING CONVERTIBLE BONDS.

Source text for Eikon:  ID:nGNE5Qd34X 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))